The Economic Burden of Multiple Sclerosis in Spain: A Population Based Study

Sicras‐Mainar, Antoni; Ruíz-Beato, Elena; Mauriño, Jorge; Ferrer,; Sáez-Zafra, Marc; Sánchez, Lyda Mayerly Salazar; Navarro‐Artieda, Ruth

doi:10.1016/j.jval.2016.09.1537

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 In multiple sclerosis (MS), a number of studies have been published, including cost of illness assessments. [4][5][6][7] The availability of disease-modifying treatments (DMTs) has led to changes in patient management and to focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain

Oreja‐Guevara

Kobelt²,

Berg³

et al. 2017

Mult Scler

View full text Add to dashboard Cite

Introduction:In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015.Results: A total of 462 patients (mean age 43 years) participated in Spain; 96% were below retirement age and of these, 45% were employed. Employment was related to disability, and MS affected productivity at work for 72% of those working. Overall, 92% and 64% of patients experienced fatigue and cognitive difficulties as a problem, respectively. Mean utility and total annual costs were estimated at 0.772 and €20,600 at Expanded Disability Status Scale (EDSS) 0-3, 0.486 and €48,500 at EDSS 4-6.5 and 0.182 and €68,700 at EDSS 7-9, respectively. The mean cost of a relapse was €2050. Conclusion: This study illustrates the burden of MS on Spanish patients and provides current data that are important for development of health policies.

show abstract

Section: Introductionmentioning

confidence: 99%

“…3 In multiple sclerosis (MS), a number of studies have been published, including cost of illness assessments. 4–7…”

Section: Introductionmentioning

confidence: 99%

New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain

Oreja‐Guevara

Kobelt²,

Berg³

et al. 2017

Mult Scler

View full text Add to dashboard Cite

show abstract

The Economic Burden of Multiple Sclerosis in Spain: A Population Based Study

Abstract: Management of burns in Nigeria is cost-effective although expensive for most Nigerians to afford. Nigerian government and health organisations should consider the support of burns patient as this will speed up their recovery, minimize disability and improve quality of life.

Cited by 1 publication

References 0 publications

New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain

New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain

Contact Info

Product

Resources

About